FDA-approved test expands options for Alzheimer's disease: Joshua Bornhorst, Ph.D.
Joshua Bornhorst, Ph.D., explains the differences between the new, FDA-approved Alzheimer's disease (AD) test and Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to give physicians flexibility and options for optima
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:32)
Can you please tell our listeners a little about yourself and your background?
(01:00)
Mayo Clinic Laboratories already offers one test for Alzheimer's disease, right?
(01:32)
Could you tell our listeners about the new FDA-approved test that Mayo Clinic Laboratories will launch soon?
(02:43)
The test results will report the ratio of the amyloid isoforms, not the individual test components, right?
(03:26)
Does the new test require a certain tube?
(04:15)
Can you provide a little more detail on the commercially available tube that will be required?
(04:36)
Which patient population would benefit most from this test?
(05:30)
Can you compare and contrast the existing Alzheimer's disease test and the new amyloid ratio evaluation?
(08:58)
Is Mayo Clinic's ADEVL the only test that measures the tau component?
(09:51)
When would one of these tests be more appropriate than the other?
(10:52)
Can you help our listeners understand what a "laboratory developed" test means?
(11:43)
From a physician's standpoint, how might this new test improve patient care?